Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report on Form 8-K on February 6, 2003, primarily to disclose a press release issued on January 30, 2003. While the filing itself does not contain extensive details about the press release's content, its inclusion as an exhibit signifies important company announcements made to the public. Investors should note that this 8-K filing is an administrative disclosure, referencing a separate press release for the substantive news. To understand the material information provided to investors, the content of the January 30, 2003 press release would need to be reviewed. This filing serves as a formal record of the company's communication with the market on that date.
Key Highlights
- 1Regeneron Pharmaceuticals (REGN) filed an 8-K report on February 6, 2003.
- 2The primary purpose of the filing was to include a press release dated January 30, 2003, as an exhibit.
- 3The 8-K itself does not contain the specific details of the press release, but directs investors to the exhibit for that information.
- 4This filing serves as a formal notification of a material event or disclosure made by the company.
- 5Investors interested in the substance of the announcement must refer to the January 30, 2003 press release.
Frequently Asked Questions
The main purpose of this 8-K filing by Regeneron Pharmaceuticals on February 6, 2003, is to formally report and include a press release dated January 30, 2003, as an exhibit. This is a standard procedure for disclosing material information to the public and the SEC.
The specific details of the announcement are contained within the press release dated January 30, 2003, which is included as Exhibit 99(a) to this 8-K filing. Investors need to review that press release for the substantive information.
This particular 8-K filing does not provide direct financial results or updates. It solely serves to attach a press release. Any financial information would be contained within that referenced press release or in subsequent SEC filings.